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1. Introduction
  Malaria is one of the most serious diseases to affect 
people in developing countries with tropical and 
subtropical climates. Plasmodium vivax (P. vivax) is the 
most widespread of the four human malaria species[1]. 
Though P. vivax is rarely lethal it can potentially lead to 
severe complication and have major deleterious effects on 
personal well-being, growth and development in endemic 
countries[1,2]. In Iran, about 65% of malaria transmission 
occurs essentially in the Sistan and Balouchistan Province 
located in south-East of the country[3]. Among malaria 
species, P. vivax has been responsible for 80% to 90% of 
malaria cases in Iran. This disease is endemic in Sistan 
& Balouchistan province in southeastern Iran, shares the 
boarder with Afghanistan and Pakistan[4].
  Innate resistance to malaria infections in humans is 
conferred by various blood group polymorphisms such as 
hemoglobinopathies (including thalassemias, HbS, HbC 
and HbE), erythrocyte polymorphisms and immunogenetic 
variants[5-7]. The Duffy protein has been identified as a 
scavenger on the red blood cell (RBC) surface eliminating 
excesses of circulating toxic chemokines, named Duffy 
Antigen Receptor for Chemokines (DARC)[8]. The Duffy 
blood group is locus located on the long arm of chromosome 
1q21-22[9] and characterized by three main alleles: FYA, 
FYB and FYO. The FYA and FYB are co-dominant alleles 
which differ by a missense mutation in the major cDNA 
transcript (G125A>Gly42Asp)[10]. The corresponding 
anti-Fya and anti-Fyb antibodies define four different 
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phenotypes; FY (a+b+), FY (a+b-), FY (a-b+) and FY (a-b-). 
The first three phenotype are common in European and 
Asian populations and the last phenotype is the predominant 
among Black population in many African ethnic groups 
and their descendants causes no obvious ill effect, and 
confers natural resistance against P. vivax infection[9-12]. 
In Fy(a-b-) phenotype, there is  a-33 T→C point mutation 
on the FYO gene promoter, which abolishes the erythroid 
gene expression by disruption the GATA transcription factor 
binding site and results in which silences the gene encoding 
the Duffy system antigens in the RBCs[13; 14]. Distribution 
of Duffy blood groups polymorphisms are important in 
areas where P. vivax predominates, because this molecule 
on the surface of RBCs acts as a receptor for the human 
malaria P. vivax[15]. Therefore, genotyping methods are 
required to assess the potential impact of these quantitative 
differences in erythrocyte FY antigen expression on P. vivax 
susceptibility. Little is known on the frequency of erythroid 
polymorphisms that confer either partial or complete 
resistance against malaria in Balouch population that is the 
large ethnic group population is in the south of Sistan & 
Balouchistan province. Here we compared the distribution 
of Duffy blood group genotypes in Balouch population 
infected with P. vivax and those non-infected individuals as 
a control group.
2. Material and methods
2.1. General material
  This case-control study took place in Iranshahr (27°, 12′ 
09′′ N; 60°, 41′ 05′′ E ) and Chabahar (25°, 17′31′′ N; 60°, 
38′35′′ E ) cities in south-east of Iran from May 2009 to 
August 2012. Balouch ethnic group make up the largest 
population of those cities[6] and all selected case and control 
individuals were Balouch from independent families born 
in this area. In patients (n=160), the P. vivax malaria was 
confirmed through thick blood film microscopically and they 
received anti-malarial treatment. The control group (n=160) 
was matched to the patients in respect to age, gender, 
ethnicity, place of birth. All control individuals had no 
malaria sign and symptoms at the initial interview and they 
had never reported suffering from a malaria attack and also 
had negative results for thick blood film. 
2.2. Methods
2.2.1. Peripheral blood samples collection
  The protocol for this study was approved by ethical 
committee of Zahedan University of Medical Sciences and 
blood samples were collected in EDTA-contained tubes 
from all participants, after informed consent. 
2.2.2. Phenotype determination
  The FY phenotypes were determined within 24 hours of 
blood collection using indirect anti-globulin technique. 
Commercial Duffy antisera anti-Fya and Fyb (CE-
Immunodiagnostika GmbH, Eschelbronn Germany) and 
anti-human globin were used according to manufacture’s 
instruction. A positive and a negative control were performed 
in a parallel experiment, which obtained from the Iranian 
Blood Transfusion Organization. 
2.2.3. Genotype determination
  Genomic DNA was extracted from whole blood cells through 
the standard phenol-chloroform procedure. Genotypes of 
Duffy blood group were determined by using PCR-RFLP 
that was modified as described before. Each PCR contained
100 ng genomic DNA, 10 pmol each primer (Primers 
sequence, location and amplicon size are showed in Table 
1), 2 nmol each dNTP, 1.0 U Taq DNA polymerase, and 
buffer, in a total reaction volume of 25毺L. The amplification 
of promoter region was done by  using the FYN1 and FYN2 
primers that flank the GATA box motif[16]. Mixture were 
incubated for 5 min at 95 曟, followed by 35 cycles, each 
lasting 60 s, with the following temperature: denaturation at 
94 曟, annealing at 65 曟 and extension at 72 曟 and a final 
elongations at 72 曟 for 5 min. Duffy RBC polymorphism 
was determined by FYAB1 sense and FYAB2 reverse sense 
primers were used that flank a segment of 392 bp in exon 2 
that included the mutation 125 G>A[16]. The amplification 
profile was 94 曟 for 5 min followed by 35 cycles, each of 
lasting 60 s, with the following temperatures: denaturation 
at 94 曟, annealing at 65 曟, and extension at 72 曟. The PCR 
products were run on 2% agarose gel to verify the fidelity 
Table 1
Sequence of primers and PCR product allele primers sequence size.
Primer/direction Sequences Location Size amplicon
FYAB /sense 5’- TCC CCC TCA ACT GAG AAC TC –3’   +63 to +82 bp  392 bp
FYAB/reverse 5’- AAG GCT GAG CCA TAC CAG AC –3’ +435 to +455 bp
FYN1/ sense 5’– CAA GGC CAG TGA CCC CCA TA –3’ -153 to -133 bp  189 bp
FYN/ reverse 5’– CAT GGC ACC GTT TGG TTC TC –3’   +17 to 36 bp
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of PCR before restriction enzymes treatment. To detect the 
125 G>A SNP, the amplification products were digested with 
endonucleases Ban1[17]. The amplification of promoter region 
were digested by Sty1[17] to determine the GATA box SNP 
at position -33 for 16 h at 37 曟 and then separated on 12% 
acryl amid gel. 
2.3. Statistical methods
  Data were analyzed by the statistical package for social 
sciences (SPSS version 11). Chi-square test was used to 
compare the proportions of Duffy genotypes in control 
and cases groups and P<0.05 was considered statistically 
significant. 
3. Results
               
  This study was performed on 320 unrelated subjects among 
Balouch population live in south-east of Iran. Of all, 160 
individuals were infected with P. vivax (case group) and 160 
subjects were uninfected with P. vivax (control group). There 
was no significant difference in the mean age of case (29.9依
16.5) years and control (29.3依14.9) years groups. 
3.1. Phenotype distributions
  The serological assays indicated that the most common 
phenotypes in case and control groups were Fy (a+b+) with 
51.9% and 41.3% respectively (P value = 0.057) (Table 2). 
3.2. Genotype distributions
  The most common Duffy genotype was FYA/FYB (46.9%) 
followed by FYA/FYA (15.3%), FYA/FYO (14.4%), FYB/FYO 
(11.9%), FYB/FYB (10%) and FYO/FYO (1.9%) (Table 3). 
3.3. Allele frequency
  The frequencies of FYA, FYB and FYO alleles were 0.471, 
0.431, and 0.097 respectively in the case compare to 0.444, 
0.353 and 0.203 respectively in control group (Table 3).
4. Discussion
                             
  Malaria is one of the most important parasitic infections 
in the worldwide. The World Health Organization estimated 
that there were 219 million cases of malaria and 660 
thousands deaths in 2010, which mainly happened in 
Africa, Asia and South America[18]. P. vivax, is one of the 
public health challenges in Sistan & Balouchistan province 
(Iran) located in a sub-tropical areas sharing borders with 
Pakistan and Afghanistan. Prevalence of Plasmodium 
species in different regions can be related to genetic factors, 
including their Duffy blood group[5-7]. The evolution of Duffy 
blood group polymorphisms has been used as a marker 
for ethnic composition. This study showed that there is a 
significant association between Duffy blood group variants 
and susceptibility or resistance to vivax malaria.                                      
  The current study results showed that the most common 
erythrocyte phenotype was Fy(a+b+), followed by Fy(a+b-), 
Fy(a-b+) and Fy(a-b-). Frequency of Duffy Fy (a+b+) 
genotype was 52% in patients compared to 41% in healthy 
participant (11% more). In two similar study Cavasini et al
in Brazilian and Mohanty et al in India recorded an 
almost 8% and 23% higher prevalence of this phenotype 
in malaria patients compared to the healthy participants, 
respectively[15,19]. Therefore, it seems that expression of the 
FYA and FYB genes in conditional heterozygote facilitate
Table 2
Comparison of Duffy phenotype using serological method in case and control groups in Balouch population in Southeast of Iran.
Erythrocyte phenotype Number observe Case/control Frequency, % Case/control Over all (%) P value
Fy(a+b-) 42/53   26.3/33.1 29.7 0.178
Fy(a-b+) 33/37  20.6/23.1 21.9 0.589
Fy(a+b+) 83/66  51.9/41.3 46.6 0.057
Fy(a-b-) 2/4  1.3/2.5   1.9 0.685
Table 3
Genotype and allele frequency of Duffy blood group in Balouch population in South-East of Iran.
Population n
Genotype frequency Allele frequency
FY*A/FY*A FY*A/FY*O FY*B/FY*B FY*B/FY*O FY*A/FY*B FY*O/FY*O FY*A FY*B FY*O
Case 160 26(16.3%) 16(10%)   22(13.8%) 11(6.9%)   83(51.9%) 2(1.3%) 0.471 0.431 0.097
Control 160 23(14.4%)    30(18.8%) 10(6.3%)   27(16.9%)   66(41.3%) 4(2.5%) 0.444 0.353 0.203
P value 0.641 0.026 0.025 0.006 0.057 0.685$ 0.563 0.170 0.012  
Overall 320 49(15.3%)    46(14.4%) 32(10%) 38(11.9%) 149(46.6%) 6(1.9%) 0.458 0.392 0.150
$: Fisher’s Exact Test.
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infection by P. vivax indicating that Fy(a+b+) individuals 
may be more prone to infection by this species of 
Plasmodium[20]. Furthermore, lower quantity of DARC was 
detected in individuals with FYA and FYB alleles than 
heterozygote individuals. This may be led to more receptors 
available in later individuals for possible variations in the 
parasite protein which binds to the human erythrocytes[20,21]. 
Therefore, susceptibility to infection may be not only 
dependent on the different levels of the expression, but also 
the specific conformation of the Fya and Fyb antigens.                     
  The results indicated that homozygous FYA allele was 
more prevalent in the control group whereas heterozygous 
FYA allele was more prevalent in the case group and FYB 
allele results were almost similar. However, FYO linked with 
FYA and FYB alleles decreased the chance of infection by 
vivax malaria. Therefore, protection against this species of 
plasmodium may be supported by a combination of FYO/
FYO genotypic with either FY (a+b-) or FY (b+b-). This 
hypothesis has been supported by In vitro studies[7] so that 
significant reduction in cytoadherence of the parasite was 
reported in RBCs expressing those phenotypes than Fy(b+b+). 
Infection by P.vivax was reported to be significantly lower 
in Duffy negative heterozygotic individuals for the FYAnull 
allele[22]. Albuquerque et al in study on 497 patients in the 
Amazonas State, Brazil, showed that FYA/FYB and FYA/
FYA genotypes had  higher levels of parasitism of P. vivax 
infection than FYB/FYO and FYA/FYO[23]. A 50% reduction 
in the Duffy protein expression on the erythrocyte was also 
reported when FYO allele were present[7,24]. Therefore, effect 
of the gene is dose-related, which may limit the invasion 
process of red blood cells by the parasite[7,21]. 
  In the current study, homozygous FYO allele was more 
frequent (2.1 times) among control group than case group 
(P<0.05). These findings may be a related to occurring 
mutation in a population as this phenotype favors resistance 
to the infection in areas where P. vivax is endemic, 
which is in accordance with some other studies[7,13,25-28]. 
Although the absence of Fy antigen has not been reported 
to be exert any deleterious effect in many ethnic Negro 
groups, its presence causes resistance against infection by
P. vivax[12,26,29,30]. Thus, where P. vivax is predominates, 
the frequency of the Fyo allele is higher than expected level 
in the population, both in heterozygotes and homozygotes 
forms. This might lead to an increasing in the number of 
Duffy-negative individuals in the population as a result of 
natural advantages selection. 
  Transmission in homozygous for FYO allele has recently 
become evident in Africa, Brazil and Malagasy[31-34] 
suggesting that this parasite is able to use alternative 
receptors, apart from Duffy, to invasive erythrocytes, 
which may have an enormous impact in P. vivax current 
distribution.
  In sum, our results support the hypothesis that individuals 
with the FYA/FYB genotype are more prone to malaria 
also increasing in number of FYO allele homozygote or 
heterozygote forms could be a result of an advantageous 
selection where P. vivax is endemic. 
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